A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

NCT00002195 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.

Conditions

  • HIV Infections

Interventions

DRUG

Amprenavir

DRUG

Lamivudine

DRUG

Zidovudine

Sponsors & Collaborators

  • Glaxo Wellcome

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002195 on ClinicalTrials.gov